BACKGROUND The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent
Several randomized and observational trials of these newer DES suggest that they permit a shorter duration of dual antiplatelet therapy (DAPT) (14) (15) (16) (17) (18) (19) (20) .
Current guidelines recommend 6 months of DAPT post-DES in stable patients (21) and 1 year of DAPT in patients with acute coronary syndrome (ACS) (21, 22) .
However, when our trial began, the guidelines (22) recommended 12 months of DAPT regardless of the clinical situation. A randomized, multicenter trial was, therefore, initiated to assess the effect of 6 versus 24 months of DAPT on medium-term clinical outcomes after coronary intervention in a real-world clinical population receiving second-generation DES.
To be sure that patients would be protected by their antiplatelet therapy, patients resistant to aspirin were excluded (23, 24) . (27, 28) .
MI was classified as Q-wave or non-Q-wave MI. (definite/probable), major bleeding (TIMI), and stroke between 6-month and 1-year follow-up was estimated to be less than but close to 2%. Sample size was calculated to detect noninferiority of short compared to long-term DAPT, with 80% power. The expected rate of events was 3%, and the noninferiority margin was set at 2%, leading to inclusion of 900 patients/arm, for a type I error of alpha ¼ 5%. With a drop-out rate of 20% in the test group and 5% in the control group, and considering a 10% rate of aspirin resistance, a total of 2,475 patients needed to be included to enable a conclusion to be drawn. Sample size was calculated considering an alpha ¼ 5%, but to be compliant with the most recent guidelines, the noninferiority confidence interval (CI) has been performed finally at 97.5%.
Statistical comparison was performed between the 6-and 24-month DAPT groups; the aspirin resistance group results were only descriptive. Baseline characteristics were compared between the 2 treatment groups by Student t test or Wilcoxon rank sum test as
appropriate for continuous variables, and chi-square test for categorical variables. Kaplan-Meier survival curves were constructed (30) , and differences between the curves were tested by the log-rank test.
Proportional hazard models (31) were used to estimate hazard ratios (HRs) and 95% CIs. Survival analysis was performed in the intention-to-treat population, with the primary endpoint as the event.
Sensitivity analysis was performed in the perprotocol population to assess robustness of results.
Statistical analyses were performed and validated using SAS version 9.4 software (SAS Institute Inc., Cary, North Carolina). Noninferiority was tested on the primary endpoint with a 1-tailed 97.5% CI. Times to primary endpoint and all secondary endpoints were also assessed on survival analysis. The group of patients with ACS was analyzed post hoc.
RESULTS
STUDY POPULATION. Figure 1 shows the trial flow chart with 2,031 patients enrolled. The trial was prematurely terminated due to recruitment problems.
After aspirin monitoring, 131 patients were classified as aspirin resistant, and were not randomized but were followed up as the aspirin-resistant group.
A total of 1,894 patients were eligible for randomization. Before 6 months, 44 patients were excluded from analysis due to an endpoint-related event (13 deaths, 10 MIs, and 2 TVRs). Thus, 1,850 patients were randomized to 24-month DAPT (n ¼ 924) versus 6-month DAPT (n ¼ 926).
The 2 test groups had similar baseline ( Table 4 , Central Illustration).
Noninferiority was established for 6-versus 24-month DAPT, with an absolute risk difference Values are n (%) or mean AE SD.
DAPT ¼ dual antiplatelet therapy. CI ¼ confidence interval; TVR ¼ urgent target vessel revascularization; other abbreviations as in Table 1 .
Gilard et al. trial, which also compared 6-to 24-month DAPT, but demonstrated an increased rate of bleeding in the long-duration arm (14) .
Regardless of the type of DES, several guidelines call for a minimum of 12 months of DAPT after DES implantation to prevent late ST (22, 33) . However, second-generation DES have been shown to have a safety profile similar to or even better than BMS (4, (11) (12) (13) 34) . No data support prolonging DAPT beyond 1 year after DES implantation. Indeed, merged data from 2 randomized stenting trials (n ¼ 2,071)
showed a nonsignificant trend for a higher rate of MI, stroke, and death at a median of 19 months of followup in patients continuing versus stopping clopidogrel 1 year after stenting (35) . Several randomized trials comparing short (3 to 6 months) versus extended (12 to 24 months) DAPT consistently showed a lack of benefit in terms of ischemic outcome but a higher risk of bleeding (14, 16, 17) . A recent meta-analysis of brief versus prolonged DAPT (>12 months) concluded that extending DAPT beyond 6 months increased bleeding risk without reducing the rate of ischemic events (15, 36) . These findings explain the modifications Abbreviations as in Tables 1 and 3 . In the overall trial population, 6-month DAPT was noninferior to 24-month treatment (p for noninferiority ¼ 0.0002), and there were no differences in stent thrombosis or bleeding complications. These endpoints did not differ significantly in the 792 (44%) high-risk patients with ACS (hazard ratio: Crossover from DAPT to single antiplatelet therapy after 6 months is possible in good aspirin responders.
However, in the present aspirin-resistant group, the rate of adverse events was also very low, probably due to overtreatment of patients with known aspirin resistance. The role of aspirin resistance monitoring in clinical practice should be questioned.
STUDY LIMITATIONS AND STRENGTHS. Due to enrollment difficulties, recruitment stopped at 2,031 patients, rather than the 2,475 patients required to have 900 analyzable patients in each group; however, as we finally had an event rate of 1.5% (compared to the 3% expected), and as we are far from the boundary, the sample size is enough for the conclusion to be 
CONCLUSIONS
The ITALIC trial showed that bleeding and thrombotic event rates were not significantly different between 6-and 24-month DAPT groups after PCI with second-generation DES, and that 6-month DAPT was noninferior to 24-month DAPT in good aspirin responders. Noninferiority was also observed in the subgroup of unstable patients (one-half of patients).
Larger trials are needed to assess the effect of antiplatelet duration in ACS patients.
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PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Following deployment of new-generation DES, 6 and 24 months of DAPT are associated with similar rates of thrombotic and bleeding events in patients who are responsive to the platelet inhibitory effects of aspirin.
TRANSLATIONAL OUTLOOK: Future research should seek to identify the specific clinical characteristics associated with benefit or harm related to shorter or longer durations of DAPT following deployment of various types of coronary stents.
